ArticleCureus2025
A Case of Waldenstrom's Macroglobulinemia Presenting as Worsening Neuropathy.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Waldenstrom's macroglobulinemia (WM) is a rare lymphoplasmacytic lymphoma characterized by proliferation of monoclonal IgM-secreting B-cells, typically presenting with anemia, hepatosplenomegaly, and lymphadenopathy. We describe a case of WM manifesting as progressive neuropathy, initially attributed to degenerative spinal disease, for which the patient underwent treatment without clinical improvement. Further evaluation revealed a monoclonal M-spike on serum protein electrophoresis (SPEP) and endoneural IgM deposition on sural nerve biopsy. Bone marrow biopsy demonstrated lymphoplasmacytic lymphoma with MYD88 L265P mutation. The patient underwent six cycles of bendamustine-rituximab with partial neurological stabilization and a significant decline in IgM levels. However, neuropathy subsequently recurred, necessitating the initiation of zanubrutinib. This case highlights the diagnostic complexity of paraproteinemic neuropathy and emphasizes the importance of considering WM in the differential diagnosis of atypical neuropathy to ensure timely intervention and mitigate irreversible nerve damage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.